Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts DYN Hot Sheet
Price: $18.50 +2.49%
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Jay Olson upgraded Dyne Therapeutics (NASDAQ: DYN) from Perform to Outperform with a price target of $40.00 (from $11.00).
For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.
Shares of Dyne Therapeutics closed at $18.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
- United Therapeutics Corp. (UTHR) PT Raised to $768 at BTIG
- Northland on SolarEdge (SEDG): 'Storage remains a bright spot for the Company'
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
